| First Author | Tomoshige K | Year | 2018 |
| Journal | Oncogene | Volume | 37 |
| Issue | 28 | Pages | 3894-3908 |
| PubMed ID | 29662194 | Mgi Jnum | J:264022 |
| Mgi Id | MGI:6192836 | Doi | 10.1038/s41388-018-0240-1 |
| Citation | Tomoshige K, et al. (2018) An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo. Oncogene 37(28):3894-3908 |
| abstractText | EGFR ligands (e.g., EGF and TGFA) have been shown to be clinically associated with poor survival in lung cancer. Since TGFA itself initiates autochthonous tumors in liver, breast, and pancreas but not in the lung in transgenic mice in vivo, it would appear that an EGFR ligand may not initiate but rather promote lung cancer. However, it has not been proven in vivo whether lung cancer is promoted by an EGFR ligand. Using transgenic mouse models conditionally expressing EGFR(L858R) or Kras(G12D) with TGFA (an EGFR ligand) in lung epithelium, we determined that TGFA promoted the growth of EGFR(L858R)-lung tumors in airway regions but not that of Kras(G12D)-lung tumors. Analysis of TCGA datasets identified DeltaNp63 and AGR2 as potential key tumor-promoting regulators, which were highly induced in the TGFA-induced EGFR(L858R)-lung tumors. The expression of AGR2 was positively correlated with the expression of TGFA in human EGFR-mutant lung adenocarcinomas. The expression of TGFA in human EGFR-mutant lung adenocarcinomas but not in the EGFR wild-type lung adenocarcinoma was associated with poor survival. These results suggest that targeting EGFR ligands may benefit patients who carry EGFR-mutant lung tumors but will not benefit patients with KRAS-mutant lung tumors. |
